Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 10/20 | 0.62 |
| ▸ | JAK2 | O60674 | 8/20 | 0.43 |
| ▸ | JAK3 | P52333 | 8/20 | 0.43 |
| ▸ | IL1B | P01584 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30108806 | 1.00 | NLRP3 (0.62) | NLRP3JAK2JAK3IL1BIRAK4 | |
| SCHEMBL28934485 | 1.00 | NLRP3 (0.62) | NLRP3JAK2JAK3IL1BIRAK4 | |
| SCHEMBL28934490 | 1.00 | NLRP3 (0.62) | NLRP3JAK2JAK3IL1BIRAK4 | |
| SCHEMBL25864237 | 0.91 | NLRP3 (0.51) | NLRP3JAK2JAK3IL1BJAK1 | |
| SCHEMBL30108739 | 0.87 | NLRP3 (0.67) | NLRP3IL1B | |
| SCHEMBL28934456 | 0.87 | NLRP3 (0.67) | NLRP3IL1B | |
| SCHEMBL28934462 | 0.87 | NLRP3 (0.67) | NLRP3IL1B | |
| SCHEMBL28934535 | 0.86 | NLRP3 (0.51) | NLRP3JAK2JAK3IL1BIRAK4 | |
| SCHEMBL30108776 | 0.86 | NLRP3 (0.51) | NLRP3JAK2JAK3IL1BIRAK4 | |
| SCHEMBL28934539 | 0.86 | NLRP3 (0.51) | NLRP3JAK2JAK3IL1BIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2024-09-05 | — | — | US | disclosed |
| CN-115433163-A | NLRP3 inflammasome inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | NLRP3, NLRP1, PYCARD | NLRP3 1/4885JAK2 938/4885JAK3 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.